Evidence map›Paper›PMID 35069563›Full record

ArticleFrontiers in immunology2021

Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.

William D Tolbert, Dung N Nguyen, Marina Tuyishime, Andrew R Crowley, Yaozong Chen, Shalini Jha, Derrick Goodman, Valerie Bekker, Sarah V Mudrak, Anthony L DeVico and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

William D TolbertInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Dung N NguyenInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Marina TuyishimeDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Andrew R CrowleyThayer School of Engineering, Dartmouth College, Hanover, NH, United States.
Yaozong ChenInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Shalini JhaDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Derrick GoodmanDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Valerie BekkerDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Sarah V MudrakDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Anthony L DeVicoDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
George K LewisDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
James F TheisPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, United States.
Abraham PinterPublic Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, United States.
M Anthony MoodyHuman Vaccine Institute, Duke University School of Medicine, Durham, NC, United States.
David EasterhoffHuman Vaccine Institute, Duke University School of Medicine, Durham, NC, United States.
Kevin WieheHuman Vaccine Institute, Duke University School of Medicine, Durham, NC, United States.
Justin PollaraDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Kevin O SaundersDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Georgia D TomarasDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Margaret AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, United States.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Marzena PazgierInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Duke University · USUniformed Services University of the Health Sciences · USDartmouth College · USRutgers, The State University of New Jersey · USUniversity of Maryland, Baltimore · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kshitij Wagh · 2017 to 2026
$40.7M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
Structural Targeting of Potentially Protective gp120 Epitopes in the C1/C2 RegionR01AI116274 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2016 to 2019
$1.5M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
NIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS P01 AI131251NIAID NIH HHS P01 AI162242NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI116274NIAID NIH HHS R01 AI129769NIH HHS K01 OD024877
6 · The paper itself

Abstract

Passive transfer of monoclonal antibodies (mAbs) of human origin into Non-Human Primates (NHPs), especially those which function predominantly by a Fc-effector mechanism, requires an

Indexed as

Antibodies, MonoclonalHIV AntibodiesImmunoglobulin GHIV-1HumansAntibodies, MonoclonalHIV AntibodiesImmunoglobulin Gantibody engineeringFc-effector functionHIVnon-human primatesrhesusization

Identifiers

PMID35069563
PMCPMC8770954
OpenAlexW4205625207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.